Loading…

Becton DickinsonBDXCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Global medical technology company making injection/infusion devices, diagnostic systems and specimen management products.

Momentum leader 93
Mkt cap
$58.9B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$425M
20-day average traded
Fwd P/E
16.3×
forward earnings
ROIC−WACC
+3.5 pp
WACC 6.4%
Hurdle
-2 pp
Req g minus delivered
Official | Implied
BBB / A-
agencies · bond market
Next earnings
78 days
4 Feb 2027
Close · USD$216.08
1D+0.3%
1W+0.7%
1M+11.5%
3M+15.2%
6M+48.1%
YTD+43.5%
1Y+46.6%
ATR %2.1%
Beta0.30
52w lowhigh1.9% off high

What Becton Dickinson does

Global medical technology company making injection/infusion devices, diagnostic systems and specimen management products.

Sells mostly disposable products, such as syringes, needles and catheters, through hospital purchasing contracts and distributors, so revenue follows procedure and patient volumes; instruments and test kits are sold alongside the consumables needed to run them. It spun off Embecta in 2022 and agreed in 2025 to combine its biosciences and diagnostics business with Waters.

Products and services

  • Medication Delivery Solutions (syringes, IV)
  • Diagnostic Systems
  • Biosciences (flow cytometry)

Customers

  • Hospitals
  • Clinical labs
  • Pharmaceutical manufacturers

Where it sits in the supply chain

  • Healthcare
  • Medical devices/diagnostics
  • Medication delivery, diagnostics…

What could go right

  • Biosciences/diagnostics growth
  • Emerging-market medication-delivery volume

What could go wrong

  • Pricing pressure in commodity medical supplies
  • Planned biosciences/diagnostics spinoff execution risk

Moat: narrow (scale, installed base, switching costs). Ubiquitous installed base of needles/syringes and diagnostic instruments across global healthcare systems.

Headquarters: Franklin Lakes, New Jersey, USA · Founded: 1897

Named competitors

Becton Dickinson at a glance

Size Becton Dickinson (BDX) is a United States Health Care company (Medical Specialties) with a market value of $58.9B, the 224th largest of 3,085 United States companies the cockpit tracks. Shares closed at $216.08 on 18 Nov 2026.

Performance Over six months the shares gained 48.1%, against +23.4% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue fell 7.4% over the last twelve months (peer median +8.7%); the operating margin is 16.1% (peer median 22.2%).

Valuation It trades at 16.3× forward earnings against a peer median of 26.3× (3rd cheapest of 21).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -2 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.5 points above its cost of capital (6.4% WACC).

Credit Becton Dickinson has 14 bonds outstanding ($10.3B), rated BBB by the agencies and trading like A- at a weighted spread of 85 bp.

Short interest Short interest is 3.0% of the free float (30 Oct 2026).

Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026BDX 149Peer median 122
Six months, rebased to 100: Becton Dickinson against the median of its 20 peers (local-currency closes).

Becton Dickinson financials

Reported figures in USD; fiscal year ends 2026-09-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue$20.2B$19.5B$21.8B$20.2B$19.4B
Revenue growth—-11%+8%+4%—
Gross profit$11.3B$9.21B$9.93B$9.12B$8.17B
EBITDA$7.24B$5.30B$5.69B$5.23B$4.36B
Net income$1.15B$1.15B$1.68B$1.71B$1.48B
Free cash flow$2.69B$2.69B$2.67B$3.07B$2.12B
Capital expenditure$672M$672M$760M$725M$874M
Total debt$16.3B$16.3B$20.0B$20.9B$16.4B

Quarterly statements and history in the cockpit →

Becton Dickinson competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%+60%-10%0%+10%+20%EWIDXXBSXSHLMDLNA7741WATGEHCELALCMTDRMD300760ILMNDXCMSYKWSTSTEBDX6-month return →1-month return →
Up and to the right = strong over both horizons. Becton Dickinson is the large dot.

Fundamentals: revenue growth against valuation

-5%0%+5%+10%20×30×40×EWIDXXBSXSHLMDLNA7741WATGEHCELALCMTDRMD300760ILMNSYKWSTMDTSTEBDXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Becton Dickinson is the large dot.

Capital: growth delivered against growth the price implies

0%+10%+20%+30%0%10%20%30%EWIDXXBSXSHLMDLNA7741WATGEHCELALCMTDRMD300760ILMNDXCMSYKWSTMDTBDXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Becton Dickinson is the large dot.

Becton Dickinson competitors and peer comparison

Head to head with its named competitors (BDX vs BAX vs ABT vs 4543.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Becton Dickinson BDX$58.9B+48%-7%16%16.3×-1.6%
Baxter International BAX$13.5B+39%+5%6%12.7×13.4%
Abbott Laboratories ABT$181B+18%+10%14%17.9×16.5%
Terumo 4543.T$24.0B+32%+15%17%27.8×8.8%

How Becton Dickinson compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Becton Dickinson against its 20 peers (data as of 18 Nov 2026)
MeasureBDXPeer medianRank in peer set
1-month return+11.5%+6.1%7th highest of 21
6-month return+48.1%+23.4%3rd highest of 21
Distance from 52-week high-1.9%-9.1%highest of 21
Revenue growth (TTM)-7.4%+8.7%lowest of 21
Operating margin16.1%22.2%7th lowest of 21
Forward P/E16.3×26.3×3rd cheapest of 21
Growth the price implies (Req g, 7 yrs)-1.6%15.0%least demanding of 21
Growth delivered (Del g)+0.3%+8.6%lowest of 21
Hurdle (Req g minus delivered)-1.9 pp+4.6 pp4th least demanding of 21
ROIC minus cost of capital+3.5 pp+4.8 pp9th lowest of 21
EV / EBITDA10.2×19.1×cheapest of 20
Net debt / EBITDA2.1×1.5×4th most indebted of 20
Bond spread85 bp75 bp3rd widest of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Becton Dickinson BDXUnited States$58.9B+48%-7%16%16.3×-1.6%+0.3%
Edwards Lifesciences EWUnited States$60.5B+27%+13%29%32.3×17.1%+6.7%
Idexx Laboratories IDXXUnited States$55.0B+26%+12%32%42.9×29.0%+9.7%
Boston Scientific BSXUnited States$63.3B-23%+9%21%14.1×5.8%+15.2%
Siemens Healthineers SHL.DEGermany$53.7B+27%+1%14%18.9×9.6%+5.6%
Medline MDLNUnited States$51.5B+8%+12%6%25.6×15.9%+9.9%
Agilent Technologies AUnited States$50.0B+56%+9%24%27.0×23.3%+5.4%
Hoya 7741.TJapan$49.0B-16%+13%32%27.7×14.1%+11.6%
Waters WATUnited States$45.8B+37%+81%10%29.1×48.1%+6.0%
GE HealthCare GEHCUnited States$37.8B+30%+7%14%15.6×5.0%+3.7%
EssilorLuxottica EL.PAFrance$91.9B+5%+8%12%24.8×18.4%+14.6%
Alcon ALC.SWSwitzerland$36.9B+18%+1%12%21.5×12.2%+6.1%
Mettler Toledo MTDUnited States$34.6B+60%+7%29%33.7×20.1%+5.5%
ResMed RMDUnited States$34.1B+16%+9%34%19.7×5.7%+12.1%
Shenzhen Mindray Bio-Medical Electronics 300760.SZChina$33.6B+15%+5%28%27.3×1.0%+9.7%
Illumina ILMNUnited States$31.8B+48%+6%21%35.2×27.2%+6.0%
Dexcom DXCMUnited States$30.8B+16%+13%24%28.0×19.6%+19.3%
Stryker SYKUnited States$121B-1%+8%25%19.9×10.7%+11.8%
West Pharmaceutical Services WSTUnited States$28.1B+32%+13%23%40.2×25.8%+7.4%
Medtronic MDTUnited States$129B+30%+10%20%16.8×9.1%+3.8%
Steris STEUnited States$25.2B+21%+8%20%21.9×14.0%+13.8%

Becton Dickinson bonds and credit

Becton Dickinson has 14 bonds outstanding with $10.3B face value. The agencies rate it BBB; its bonds trade like A-. Weighted yield 5.24%, a spread of 85 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Becton Dickinson's main competitors?
Named competitors: Baxter International (BAX), Abbott Laboratories (ABT), Terumo Corporation (4543.T). The cockpit's measured peer set (industry) also includes Edwards Lifesciences (EW), Idexx Laboratories (IDXX), Boston Scientific (BSX), Siemens Healthineers (SHL.DE), Medline (MDLN), Agilent Technologies (A).
Is Becton Dickinson expensive compared with its peers?
On forward p/e it trades at 16.3× against a peer median of 26.3×, 3rd cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -2 pp: the price already allows for a slowdown.
How has Becton Dickinson stock performed?
Over six months to 18 Nov 2026 the shares returned +48.1% against +23.4% for the median peer; over one year +46.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.